20.10

0.70% 0.14

After Hours: 20.10

Syndax Pharmaceuticals Inc (SNDX)

Overview News Price History Option Chain Financials Discussions Forecast

Syndax Pharmaceuticals Inc stock is traded at $20.10, with a volume of 1.59M. It is up +0.70% in the last 24 hours and down -20.08% over the past month. Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Previous Close:

$19.96

Open:

$20.02

24h Volume:

1.59M

Relative Volume:

1.07

Market Cap:

$1.78B

Revenue:

$172.60M

Net Income/Loss:

$-285.42M

P/E Ratio:

-6.0977

EPS:

-3.2963

Net Cash Flow:

$-323.17M

1W Performance:

-4.78%

1M Performance:

-20.08%

6M Performance:

+33.11%

1Y Performance:

+48.12%

1-Day Range:

$19.45

$20.15

1-Week Range:

$19.00

$21.55

52-Week Range:

$8.58

$25.59

Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile

Name

Syndax Pharmaceuticals Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

781-419-1400

Address

730 THIRD AVENUE, NEW YORK, MA

Employee

298

Twitter

@syndax

Next Earnings Date

2026-04-30

Latest SEC Filings

SNDX's Discussions on Twitter

Compare SNDX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SNDX Syndax Pharmaceuticals Inc	20.10	1.77B	172.60M	-285.42M	-323.17M	-3.2963
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-16-25	Resumed	H.C. Wainwright	Buy
Sep-10-25	Resumed	Stifel	Buy
Sep-04-25	Resumed	Guggenheim	Buy
Aug-05-25	Reiterated	BTIG Research	Buy
Jul-10-25	Initiated	Goldman	Buy
Oct-24-24	Initiated	UBS	Buy
Jun-28-24	Initiated	Jefferies	Buy
Jan-31-24	Downgrade	Scotiabank	Sector Outperform → Sector Perform
Dec-22-23	Initiated	Mizuho	Buy
Oct-25-23	Initiated	BofA Securities	Buy
Oct-11-23	Initiated	Goldman	Buy
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Jul-11-23	Initiated	Guggenheim	Buy
Apr-17-23	Resumed	BTIG Research	Buy
Jan-31-23	Initiated	Stifel	Buy
Jan-03-23	Initiated	JP Morgan	Overweight
Jul-28-22	Resumed	B. Riley Securities	Buy
Apr-11-22	Initiated	H.C. Wainwright	Buy
Feb-15-22	Initiated	Goldman	Buy
Jun-04-21	Resumed	Robert W. Baird	Outperform
May-25-21	Initiated	Citigroup	Buy
Feb-18-21	Initiated	B. Riley Securities	Buy
Dec-03-20	Initiated	Stifel	Buy
May-22-20	Upgrade	Citigroup	Neutral → Buy
May-22-20	Downgrade	H.C. Wainwright	Buy → Neutral
May-18-20	Downgrade	Citigroup	Buy → Neutral
May-11-20	Reiterated	H.C. Wainwright	Buy
Mar-04-20	Initiated	Barclays	Overweight
Jan-13-20	Reiterated	H.C. Wainwright	Buy
Mar-08-19	Reiterated	H.C. Wainwright	Buy
Jan-04-19	Initiated	Robert W. Baird	Outperform
Jan-05-18	Initiated	B. Riley FBR, Inc.	Buy
Mar-16-17	Initiated	FBR & Co.	Outperform
Mar-02-17	Initiated	Instinet	Buy
Oct-07-16	Initiated	Guggenheim	Buy
Mar-28-16	Initiated	Citigroup	Buy
Mar-28-16	Initiated	JMP Securities	Mkt Outperform
Mar-28-16	Initiated	Morgan Stanley	Overweight

View All

Syndax Pharmaceuticals Inc Stock (SNDX) Latest News

08:42 AM

HC Wainwright Has Optimistic Outlook of SNDX Q2 Earnings - MarketBeat

08:42 AM

06:28 AM

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year - simplywall.st

06:28 AM

May 04, 2026

(SNDX) Risk Channels and Responsive Allocation - Stock Traders Daily

May 04, 2026

Biotech Momentum Builds As Syndax Pharmaceuticals Draws Market Attention - Kalkine Media

May 04, 2026

Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 6.6% Following Analyst Upgrade - MarketBeat

May 04, 2026

Stifel raises Syndax Pharmaceuticals stock price target on therapy outlook By Investing.com - Investing.com Canada

May 04, 2026

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Just Released Its First-Quarter Earnings: Here's What Analysts Think - 富途牛牛

May 04, 2026

HC Wainwright Has Optimistic Outlook of SNDX FY2030 Earnings - MarketBeat

May 04, 2026

May 03, 2026

MSN Money - MSN

May 03, 2026

Syndax Pharmaceuticals (SNDX) Narrows Q1 Loss To US$42.7 Million Challenging Bearish Narratives - Sahm

May 03, 2026

May 02, 2026

Net current asset value per share of Syndax Pharmaceuticals Inc – DUS:1T3 - TradingView

May 02, 2026

Syndax Pharmaceuticals Q1 Loss Narrows, Revenue Rises - Moomoo

May 02, 2026

Syndax Pharmaceuticals Reports Over $100 Million in Q1 Combined Sales - HarianBasis.co

May 02, 2026

Jefferies Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $37 - Moomoo

May 02, 2026

May 01, 2026

Syndax Pharmaceuticals 1Q Loss $42.7M >SNDX - Moomoo

May 01, 2026

Syndax (SNDX) Narrows Losses as Revuforj and Niktimvo Gain TractionWhat’s Really Shifting? - Yahoo Finance

May 01, 2026